Loading market dashboard
Quest Diagnostics Incorporated
DGXHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here is how Quest Diagnostics (DGX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
SECAUCUS, N.J., May 19, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on July 22, 2026 to shareholders of record of Quest Diagnostics common stock on July 8, 2026.
Quest Diagnostics gains from DIS growth, advanced diagnostics uptake and AI-driven efficiencies, though debt levels and healthcare reimbursement risks remain concerns.
Almost half of S&P 500 stocks are down for the year, but a bunch show signs they are reviving. Our screen spotlights the most promising.
Guidance upgrades are generally among the most bullish announcements a company can make, signaling that the outlook is even better than previously expected.
Quest Diagnostics delivered strong Q1 results with 9.2% revenue growth and 13% EPS growth, driving management to raise 2026 guidance. DGX's growth is fueled by advanced diagnostics, robust consumer and hospital channels, and efficiency gains from AI and automation. Key risks include margin pressure from lower-priced partnership volumes and potential Medicare reimbursement cuts under PAMA.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
SECAUCUS, N.J., April 27, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the "Notes") under Quest Diagnostics' shelf registration statement.
AEGON ASSET MANAGEMENT UK Plc cut its holdings in Quest Diagnostics Incorporated (NYSE: DGX) by 23.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,605 shares of the medical research company's stock after selling 27,786
Quest Diagnostics delivered Q1 2026 revenue of $2.9 billion (+9.2% YoY) and EPS of $2.24 (+15.5% YoY), but shares dipped post-earnings. DGX maintains a strong core business with high barriers to entry, steady but unspectacular growth, and industry-leading market access. Forward P/E is ~19x and P/S
Cwm LLC lessened its position in Quest Diagnostics Incorporated (NYSE: DGX) by 28.4% in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 18,950 shares of the medical research company's stock after selling 7,532 shares during the quarter. Cwm LLC's holdings in Quest
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Quest Diagnostics Incorporated (NYSE:DGX) on Tuesday reported upbeat earnings for the first quarter on Tuesday.
On April 21, 2026, Quest Diagnostics Inc (DGX) shares rose 4.5% to a current price of $205.04. This move is part of a broader uptrend, with the stock experienci
Quest Diagnostics Incorporated (DGX) Q1 2026 Earnings Call Transcript
DGX posts Q1 2026 earnings and revenue beat, with adjusted EPS up 13% and shares rising in pre-market trading.
Quest Diagnostics (DGX) came out with quarterly earnings of $2.5 per share, beating the Zacks Consensus Estimate of $2.37 per share. This compares to earnings of $2.21 per share a year ago.
Quest Diagnostics on Tuesday raised its forecast for 2026 profit and revenue after posting first-quarter results above Wall Street estimates, citing resilient demand for routine diagnostic testing.
First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growth First quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted diluted EPS of $2.50, up 13.1% from 2025 Full year 2026 reported diluted EPS now expected to be between $9.58 and $9.78; and adjusted diluted EPS is expected to be between $10.63 and $10.83 SECAUCUS, N.J., April 21, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Fourteen City of Hope sites across the U.S. participating in research using the Haystack MRD ctDNA Test in patients with breast, colorectal, ovarian, and prostate cancer SECAUCUS, N.J. and LOS ANGELES, April 16, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, is implementing Haystack MRD®, a highly accurate circulating-tumor DNA (ctDNA) minimal residual disease (MRD) test, for clinical trial participants with solid tumor cancers to help guide disease management for patients being treated for breast, colorectal, ovarian and prostate cancer.
DGX heads into Q1 earnings with steady growth expectations, but estimate cuts and a negative ESP could temper the outlook.
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Capital Management Associates Inc acquired a new stake in shares of Quest Diagnostics Incorporated (NYSE: DGX) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 5,900 shares of the medical research company's stock, valued at approximately $1,024,000. A number of other institutional
Foster and Motley Inc. lowered its position in Quest Diagnostics Incorporated (NYSE: DGX) by 20.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,547 shares of the medical research company's stock after selling 5,015 shares during the period. Foster and
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Delta Capital Management LLC reduced its stake in Quest Diagnostics Incorporated (NYSE: DGX) by 12.8% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 17,710 shares of the medical research company's stock after selling 2,600 shares during the quarter. Quest Diagnostics accounts for approximately 1.1% of
Assenagon Asset Management S.A. raised its stake in Quest Diagnostics Incorporated (NYSE: DGX) by 346.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,949 shares of the medical research company's stock after acquiring an additional 19,361 shares during the
SECAUCUS, N.J., March 19, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report first quarter 2026 financial results on Tuesday, April 21, 2026, before the market opens.
Danica Pension Livsforsikringsaktieselskab purchased a new position in Quest Diagnostics Incorporated (NYSE: DGX) in the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 70,846 shares of the medical research company's stock, valued at approximately $13,502,000. Danica Pension Livsforsikringsaktieselskab owned 0.06% of Quest Diagnostics at the end
An aging population and rising AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, OPCH and ADUS stand to benefit.
8 Knots Management LLC grew its position in Quest Diagnostics Incorporated (NYSE: DGX) by 56.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 275,344 shares of the medical research company's stock after purchasing an additional 98,806 shares during the period. Quest Diagnostics makes
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
SECAUCUS, N.J., March 12, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that its board of directors has elected Timothy (Tim) Wentworth, a highly seasoned business leader, to serve as a director.
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
Quest Diagnostics Incorporated (DGX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Quest Diagnostics posts strong gains from physician and hospital channels while advancing AI-powered solutions.
Cresset Asset Management LLC raised its position in shares of Quest Diagnostics Incorporated (NYSE: DGX) by 78.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,129 shares of the medical research company's stock after acquiring an additional 3,126 shares
Blair William and Co. IL raised its holdings in shares of Quest Diagnostics Incorporated (NYSE: DGX) by 7.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 97,918 shares of the medical research company's stock after acquiring an additional
